Biotechnology company creating a new class of precision immuno-oncology medicines called immune normalizers that free the body’s normal immunity against cancer.
Boston, MA and West Haven, CT
Joined October 2022
- Tweets12
- Following4
- Followers34
- Likes0
Today is #AdministrativeProfessionalsDay, and the Normunity team is sending a special thank you to Suzanne, who keeps us all on track as a stellar contributor to our success and progress in our fight against cancer.
Today we announced a multi-program collaboration that leverages Alloy’s high-velocity antibody discovery offering to accelerate Normunity’s novel precision #ImmunoOncology pipeline. #ImmuneNormalizers
businesswire.com/news/home/2…
Normunity was well represented at SITC Friday night by our very own CEO Rachel Humphrey who was on stage with the Checkpoints Band! #SITC2022 #Checkpoints
Congratulations to the Normunity team for today’s exciting launch. Looking forward to great things and #ImmuneNormalizers to come. #NormunityAgainstCancer
normunity.com/
Normunity has launched with 1) a powerful premise to reach novel I-O targets to free normal immunity, 2) a unique R&D model working with the Lieping Chen lab and 3) strong momentum to advance life-changing medicines for patients. #NormunityAgainstCancer
normunity.com/
Normunity’s pipeline of novel cancer immunotherapies is drawn from the ongoing & interactive academic-biotech research leveraging proprietary discovery platforms from the lab of Dr. Lieping Chen at Yale School of Medicine.
#NormunityAgainstCancer
normunity.com/
Introducing Normunity, opening new frontiers in immuno-oncology. We reveal hidden mechanisms to free the immune system to work normally against cancer. These are novel targets for our new class of #ImmuneNormalizers to cure cancer. #ImmunoOncology
normunity.com/